Clay B. Siegall is quite optimistic about the future being very bright for ADCs as well as Seattle Genetics, Inc. One reason is that ADCETRIS® by Seattle Genetics is the first one in a new type of ADCs. The next step that will be taken by Seattle Genetics will be in this field of ADCs. They will try for a decision from the FDA regarding the supplemental Biologics License Application. They will require it for ADCETRIS that is in the AETHERA setting. This can be used for consolidation treatment post-transplant. This is done for those Hodgkin lymphoma patients who are at a higher risk of relapse or perhaps progression. Nearly 50 percent of HL patients can be at this risk, and they may have to undergo an autologous stem cell transplant. This is when they risk a relapse. Now few therapeutic advances have been there that help in improving the patient outcomes.
This is where Clay B. Siegall mentions the other phase 3 clinical trials that are going on. Namely, they are ALCANZA, ECHELON-1 besides ECHELON-2. Over here, ALCANZA refers to a randomized trial of ADCETRIS. This year a complete enrollment to ALCANZA can be expected. These ECHELON trials will help to redefine the way in which the frontline HL along with the mature T-cell lymphoma patient is getting treated. Now, this can be done by the addition of ADCETRIS into the standard regimen. In this, its most toxic agents will be dropped. There will be a complete enrollment to ECHELON-1 that is expected to complete by this year. Between 2017 and 2018, the data readouts will also get completed and can be used for the trial.
Once the trials on ADCETRIS are completed, the programs on seven clinical-stages will begin. These lead ADC programs will have SGN-CD33A that can be used in acute myeloid leukemia. Next will be SGN-CD19A that can be used in non-Hodgkin lymphoma. These products have generated encouraging data already as stated by Clay B. Siegall.
Next, Clay Siegall has spoken about doing collaborations with several leading biotechnology companies along with pharmaceutical companies. He is talking about technology that can empower more than 20 of the ADCs which are in the process of clinical development.